KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash from Financing Activities (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Cash from Financing Activities for 6 consecutive years, with $132.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 1140.77% year-over-year to $132.0 million, compared with a TTM value of $521.5 million through Dec 2025, up 71.49%, and an annual FY2025 reading of $521.5 million, up 71.49% over the prior year.
  • Cash from Financing Activities was $132.0 million for Q4 2025 at Recursion Pharmaceuticals, down from $251.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $463.7 million in Q2 2021 and bottomed at -$11.1 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $78.9 million, with a median of $15.2 million recorded in 2024.
  • Peak annual rise in Cash from Financing Activities hit 121288.74% in 2021, while the deepest fall reached 104.83% in 2021.
  • Year by year, Cash from Financing Activities stood at $3.8 million in 2021, then skyrocketed by 3779.24% to $147.3 million in 2022, then crashed by 45.23% to $80.7 million in 2023, then crashed by 86.81% to $10.6 million in 2024, then surged by 1140.77% to $132.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for RXRX at $132.0 million in Q4 2025, $251.3 million in Q3 2025, and $97.7 million in Q2 2025.